Six Years, Not Six Minutes: In Ruti Aga's Case the Paperwork Is the Offence

The paper that landed on my desk was not a medical authorisation. It was a forged document bearing an institution's name. The clinic whose letterhead it carried has stated plainly that the pad was withdrawn from use long ago. The person who wrote it is not a registered physician. He is a member of Ruti Aga's family. Ethiopia's marathon runner has been handed a six-year ban, and the heaviest part of that decision rests on a single sheet of paper. 10 September. No stadium, no finishing tape. A date, a notice, and a number — six. Aga is 32. When the sanction expires she will be 38. Marathon careers can stretch, but six years outside competition and testing is not merely lost time. It is the loss of a coach, an agent, a training group, an invitation network, all at once. I began with the ledger, and the legend arrived later. The largest entry in Aga's ledger is the 2026 Tokyo Marathon — a World Marathon Major victory. Beside it sit three further Major runner-up finishes. Those four lines define her, and they do not describe dominance. She sits roughly in the global top 15 to 25 of her generation: consistent, podium-grade, never the athlete the event was built around. That calibration matters, because the financial weight of a ban falls hardest exactly at this tier. I watched that Tokyo morning in 2026. My notes from the day gave more space to pacing discipline than to the clock — where the surge came, where she restrained herself. That is the real craft of the marathon. But in this context one methodological point has to be stated: road racing has no wind gauge, so a marathon mark is never as cleanly comparable as a track mark. Course profile, altitude, women-only versus mixed pacing, and the super-shoe dividend — leave any of those four out and you are comparing two different things while pretending they are one. In March she won a half marathon in China. I do not have the race name, the winning time, or the course. What I have is a positive sample collected after that win. In the road-racing hierarchy, events of this kind are usually label-level: the main draw is the appearance fee, and the testing footprint is set by the local anti-doping organisation and targeted AIU work rather than by the race's commercial profile. That is the classic exposure zone — high fee, low surveillance. Methylprednisolone is a glucocorticoid, an anti-inflammatory, precisely the class a marathoner with a knee complaint might be given. Under the WADA framework, glucocorticoids are prohibited in competition via injectable, oral, or rectal routes. Out of competition, with proper clearance, use is defensible. So the question in this case is not whether she took medication. The question is whether it was in her system in competition, and which route she chose to explain that. This is where the ledger flips. A corticosteroid for a knee problem is entirely credible for a marathoner. The injection is not what produced the sanction. What produced it is the documentary trail built around the injection: a family member presenting as a physician, a claim about an old prescription pad from a former workplace, and a clinic that flatly denied it. That single narrative converted a doping case into a tampering case, and the bulk of the sanction came from there. The material I have identifies a four-year tampering component as the driver of the six-year total, with no indication of any prior sanction. The full reasoned decision is not in front of me, so I hold that apportionment as provisional. The number that matters now is not a time. It is an annulment. The March half marathon result will be disqualified — title, prize money, ranking points. Because the sample was collected at that race, the first instalment of the punishment lands on that result. The 2026 Tokyo title is untouched by this decision. For agents and organisers it raises a separate set of questions about appearance fees, winner announcements, and promotional use. The financial arithmetic is harsh, and harsh is not a reason to skip it. An athlete with one Major win and three Major runner-up finishes earns primarily from appearance fees and podium bonuses, not global endorsements. A six-year ban does not trim that income at the margin. It stops it almost entirely. A return at 38 to Major-level racing is highly improbable; six years away from the altitude training belt, the agent network, and the rhythm of competition erodes professional existence, not just fitness. Here is where I part company with the standard reading. The story is being consumed as a doping story — some as fraud, some as victimhood. The ledger proposes a third reading: this is a story about the absence of professional medical support. Had a licensed team physician with TUE literacy handled a knee complaint, the glucocorticoid question would have been documented, and any doubt about in-competition presence resolved in advance. That channel did not exist here. In its place: a relative, an old pad, and a claim the clinic itself rejected. Second, correlation is not causation. Presence of a substance proves presence, nothing more. A glucocorticoid is not an anabolic steroid; its plausible performance benefit in a marathon is marginal, and its actual job is reducing inflammation. The sentence "she took it to go faster" is not supported by the ledger. But the forged document strikes exactly where the defence "the drug was there, the purpose was treatment" could have stood. Fabricate the paperwork and doubt stops being doubt. The weight of the sanction sits on the paper, not the vial. Third, reading a detection as proof the system works strikes me as dangerous. At a fee-driven label race, where the testing footprint is not set by the race's commercial profile, a positive result shows the system functioning — and simultaneously reminds us how many comparable cases are never tested at all. The real discovery in this case is the low-visibility zone of road racing, not Aga's name. And I will write down what I do not know, because a blank cell in a ledger is also information. Five gaps are obvious: no race name, no winning time, no sample type, no year of decision, no course profile. Add a sixth — her peak marks of 2026 and 2026 sit inside the first carbon-plate generation, and without course-level data that technological dividend cannot be separated out. I audit records the way others read scripture: stopping at every word, counting every gap. Looking forward, three things need watching. Whether the full reasoned decision is published, and specifically how the six years are broken down. Whether the March race name and time surface, and whether the organiser says anything about its testing protocol. And whether the number survives a CAS challenge. A valuation is a story with a decimal point — and in this case the decimal point was placed after 10 September, beneath a prescription pad.